Insider · CIK 0001809747
Harout Semerjian
Files at GERN (GERON CORP), CBIO (GLYCOMIMETICS INC). First filing -, latest -.
In brief
Harout Semerjian files SEC Form 4 as CEO, president and director at GERN (GERON CORP), and also at CBIO (GLYCOMIMETICS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Harout Semerjian has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 7, 2025 | GERN GERON CORP | AGrant or award Stock Option (right to buy)derivative | +7,000,000 | $0.00 | $0 | 7,000,000 | Aug 8, 2025 |
| Aug 7, 2025 | GERN GERON CORP | AGrant or award Stock Option (right to buy)derivative | +4,000,000 | $0.00 | $0 | 4,000,000 | Aug 8, 2025 |
| Jan 12, 2024 | CBIO GLYCOMIMETICS INC | AGrant or award Employee Stock Option (right to buy)derivative | +695,000 | $0.00 | $0 | 695,000 | Jan 17, 2024 |
Questions about Harout Semerjian
Answered from the filings on this page, as of the latest one.
Is Harout Semerjian buying or selling?
Harout Semerjian has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Harout Semerjian's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Harout Semerjian has 0.
Where does Harout Semerjian file Form 4?
Harout Semerjian has filed Form 4 at GERN (GERON CORP) as President and CEO; CBIO (GLYCOMIMETICS INC) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.